NOTTINGHAM, England–(BUSINESS WIRE)–Quotient
Sciences (“Quotient”), the drug development services organization,
announces it has acquired Pharmaterials,
a contract development and manufacturing organization (CDMO) based in
Reading, U.K.. The acquisition strengthens and expands Quotient’s
formulation and manufacturing services footprint in the U.K., and
further supports the growth of Quotient’s Translational
Pharmaceutics® platform, following the acquisitions of
SeaView Research and QS Pharma in February 2017.
Pharmaterials has a significant track record in supporting the
development of small molecule drug products for oral and inhaled
delivery. The company’s portfolio of services spans the characterization
and optimization of drug substance physical forms, the development of
preclinical and clinical formulations, through to clinical trial
manufacturing and subsequent global drug product supply. The business
was founded in 2000 and is located in a 48,000-square feet facility that
houses 13 GMP manufacturing suites, with space for future expansion.
Mark Egerton, CEO, Quotient Sciences, said: “The
acquisition of Pharmaterials strengthens Quotient’s service portfolio
from preclinical formulation development through to commercial
manufacturing. The addition expands Quotient’s global CDMO services with
added capacity and capabilities to better serve our clients’ needs.”
With over 700 employees, six operating sites across the U.S. and U.K.
and a 30-year track record for quality services, Quotient is focused on
delivering an innovative portfolio of services that are proven to
shorten development timelines, reduce associated costs and accelerate
the delivery of new medicines to patients globally.
For further information, please contact:
Tel: +44 (0)7787 502 947
(0)115 931 5102